<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02519595</url>
  </required_header>
  <id_info>
    <org_study_id>R1-2013-88</org_study_id>
    <nct_id>NCT02519595</nct_id>
  </id_info>
  <brief_title>Optimal Dosing of Ketamine for Procedural Sedation and Analgesia in Children</brief_title>
  <official_title>Optimal Dosing of Ketamine for Procedural Sedation and Analgesia in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a wide variation of published IV ketamine dosing regimens used for procedural
      sedation in children in the Emergency Department (ED). The purpose of the study was to
      compare the efficacy, duration of sedation and adverse events between the three commonly
      administered doses of IV ketamine (1 mg/kg, 1.5 mg/kg and 2 mg/kg) using the traditional
      administration method of 30-60 second infusion for ED sedation in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a prospective, double-blind, randomized controlled trial of children aged 3 to 18
      years who received IV ketamine for procedural sedation and analgesia (PSA) for orthopedic
      procedures, incision and drainage (I &amp; D) of skin abscess and laceration repair in an inner
      city, tertiary care pediatric ED. Random sequence allocation was performed using a
      computer-generated, random number table by the study research pharmacist. The study
      participants were grouped according to their age as follows (1) 3-6 years (2) 7-12 years (3)
      13-18 years. Children from each age group were assigned in equal numbers to all three
      ketamine dosing (1 mg/kg, 1.5 mg/kg and 2 mg/kg) groups using random permuted blocks
      stratified by the pharmacist. All ED staff including the physician and the nurse in charge of
      sedation, the study research assistant, the parents/guardians and the study subjects were
      blinded to the randomization and the group assignments. The dosage and administration of
      additional doses of ketamine were left to the discretion of the ED physician in charge of the
      sedation. The research team did not participate in the clinical care including sedation of
      the patient. Children were monitored per ED policy for the entire duration of sedation. Three
      1 ml blood samples for the ketamine assay was collected from the existing intravenous access
      at three time intervals: 3-5 minutes after ketamine administration, at midpoint during the
      procedure and prior to discharge of the patient from the ED. In the event a second dose of
      ketamine was administered, a 4th 1 ml sample was collected 3-5 minutes after the 2nd dose in
      children weighing &gt;20 kilograms. Patient demographics, procedure type, NPO status , ASA
      classification, pain medication administered prior to sedation (timing, dosage and type),
      number and total doses of ketamine administered after the initial study dose, sedation
      efficacy and duration, length of procedure, adverse events related to sedation, interventions
      performed to address the adverse events and patient disposition were collected. The study
      research assistant also performed a follow up phone call to the parents/caregivers of the
      children 48 hours after ED discharge to collect information on adverse events that happened
      at home . A total of 3 attempts were made to contact the parent/caregiver after which the
      participant was considered as lost to followup.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sedation Efficacy</measure>
    <time_frame>Participants will be assessed after study drug adminsitration and the maximum depth of sedation achieved recorded. Approximately 2 hours</time_frame>
    <description>Measure sedation depth using Ramsay Sedation Scale. Varies from 1-6 with 1: anxious, agitated, restless 2: Cooperative, oriented, tranquil 3: responsive to commands 4: Brisk response to light glabellar tap or auditory stimulus 5: Sluggish response to light glabellar tap or loud auditory stimulus 6 being no response to light glabellar tap or loud auditory stimulus. Higher the score, greater is the depth of sedation. Use of ketamine usually provides a depth of sedation of 5 or 6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>Patients will be assessed during the procedure after administration of sedation medicaiton. Approximately 30 minutes</time_frame>
    <description>Measure pain using self reported Wong Baker faces pain rating scale prior to sedation, during sedation and prior to discharge.The scale shows a series of faces ranging from a happy face at 0, &quot;No hurt&quot; to a crying face at 10 &quot;Hurts worst&quot;. The patient must choose the face that best describes how they are feeling. The score has values of 0(no hurt), 2(hurts little bit), 4(hurts little more), 6(hurts even more), 8(hurts whole lot),10 (hurts worst). The patient chooses one number that describes the pain best (eg. Either a 2 or 4).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sedation Duration</measure>
    <time_frame>Patients will be assessed during the length of time from administration of sedation medication until ready for discharge, Approximately 3 hours</time_frame>
    <description>Length of sedation was defined as the time duration from the administration of study medication until ready for discharge using standardized discharge criteria (Aldrete scoring &gt;9) followed at our institution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional Dose</measure>
    <time_frame>Patients will be assessed during procedure . Approximately 1 hours</time_frame>
    <description>Number of participants to whom additional doses of ketamine administered apart from the study dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Patients will be assessed after administration of medication until discharge and will have a follow up phone call 48 hours after discharge for 3 attempts. 5 days.,</time_frame>
    <description>Adverse events secondary to sedation experienced by the patient and interventions performed to overcome them</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation Satisfaction</measure>
    <time_frame>At the end of the procedure. Approximately 1 hour</time_frame>
    <description>Consultants will be asked to rate their level of satisfaction with sedation on a Likert Scale of 1-3</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Moderate, Deep Sedation</condition>
  <arm_group>
    <arm_group_label>ketamine IV 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine IV 1.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine IV 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine IV 1mg/kg</intervention_name>
    <description>Intervention: Ketamine IV 1mg/kg</description>
    <arm_group_label>ketamine IV 1 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine IV 1.5mg/kg</intervention_name>
    <description>Intervention: Ketamine IV 1.5 mg/kg</description>
    <arm_group_label>Ketamine IV 1.5 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine IV 2mg/kg</intervention_name>
    <description>Intervention: Ketamine IV 2 mg/kg</description>
    <arm_group_label>Ketamine IV 2 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children 3 -18 years of age

          -  Belonging to American Society of Anesthesiologists (ASA) classification 1 or 2

          -  Receiving IV ketamine for procedural sedation for orthopedic procedures,

          -  Incision and Drainage of skin abscess and laceration repair

        Exclusion Criteria:

          -  Contraindications to use of Ketamine

          -  Parents or legal guardian not available or declined to provide informed consent

          -  Child declined to provide assent,

          -  Patients that received intramuscular ketamine,

          -  Patient that received benzodiazepines in addition to ketamine

          -  Children weighing &gt;100 kilogram

          -  Children with developmental disabilities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2015</study_first_posted>
  <results_first_submitted>April 22, 2016</results_first_submitted>
  <results_first_submitted_qc>August 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 12, 2016</results_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Michigan</investigator_affiliation>
    <investigator_full_name>Nirupama Kannikeswaran</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics and Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>Procedural sedation</keyword>
  <keyword>ketamine</keyword>
  <keyword>children</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Conducted at a level 1 trauma Pediatric Emergency Department from July 1st 2010 to August 31st 2012. We enrolled a convenience sample of eligible patients. Study participants were identified using the electronic medical tracking board which lists the presenting complaint and after need for IV ketamine sedation was established with physician.</recruitment_details>
      <pre_assignment_details>11 consented patients were excluded as sedation and procedure was performed in the operating room rather than in the Emergency Department</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketamine IV 1 mg/kg</title>
          <description>Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
Ketamine IV 1mg/kg: Intervention: Ketamine IV 1mg/kg</description>
        </group>
        <group group_id="P2">
          <title>Ketamine IV 1.5 mg/kg</title>
          <description>Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
Ketamine IV 1.5mg/kg: Intervention: Ketamine IV 1.5 mg/kg</description>
        </group>
        <group group_id="P3">
          <title>Ketamine IV 2 mg/kg</title>
          <description>Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
Ketamine IV 2mg/kg: Intervention: Ketamine IV 2 mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Children aged3-18 years who received procedural sedation and analgesia in the Emergency Department</population>
      <group_list>
        <group group_id="B1">
          <title>Ketamine IV 1 mg/kg</title>
          <description>Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
Ketamine IV 1mg/kg: Intervention: Ketamine IV 1mg/kg</description>
        </group>
        <group group_id="B2">
          <title>Ketamine IV 1.5 mg/kg</title>
          <description>Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
Ketamine IV 1.5mg/kg: Intervention: Ketamine IV 1.5 mg/kg</description>
        </group>
        <group group_id="B3">
          <title>Ketamine IV 2 mg/kg</title>
          <description>Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
Ketamine IV 2mg/kg: Intervention: Ketamine IV 2 mg/kg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>3-6 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7-12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13-18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AMerican Society of Anesthesiologists (ASA) Category</title>
          <description>The purpose of the ASA is to evaluate the degree of a patient's &quot;sickness&quot; or &quot;physical state&quot; before selecting the sedative or before performing the procedure. There are 6 categories
Healthy person.
Mild systemic disease.
Severe systemic disease.
Severe systemic disease that is a constant threat to life.
A moribund person who is not expected to survive without the operation.
A declared brain-dead person whose organs are being removed for donor purposes.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ASA Class 1, A normal healthy patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASA class 2, Mild systemic disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASA class 3, Severe systemic disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Procedure Type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Fracture/Dislocation Reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incision and Drainage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laceration Repair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sedation Efficacy</title>
        <description>Measure sedation depth using Ramsay Sedation Scale. Varies from 1-6 with 1: anxious, agitated, restless 2: Cooperative, oriented, tranquil 3: responsive to commands 4: Brisk response to light glabellar tap or auditory stimulus 5: Sluggish response to light glabellar tap or loud auditory stimulus 6 being no response to light glabellar tap or loud auditory stimulus. Higher the score, greater is the depth of sedation. Use of ketamine usually provides a depth of sedation of 5 or 6.</description>
        <time_frame>Participants will be assessed after study drug adminsitration and the maximum depth of sedation achieved recorded. Approximately 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine IV 1 mg/kg</title>
            <description>Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
Ketamine IV 1mg/kg: Intervention: Ketamine IV 1mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Ketamine IV 1.5 mg/kg</title>
            <description>Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
Ketamine IV 1.5mg/kg: Intervention: Ketamine IV 1.5 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Ketamine IV 2 mg/kg</title>
            <description>Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
Ketamine IV 2mg/kg: Intervention: Ketamine IV 2 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Sedation Efficacy</title>
          <description>Measure sedation depth using Ramsay Sedation Scale. Varies from 1-6 with 1: anxious, agitated, restless 2: Cooperative, oriented, tranquil 3: responsive to commands 4: Brisk response to light glabellar tap or auditory stimulus 5: Sluggish response to light glabellar tap or loud auditory stimulus 6 being no response to light glabellar tap or loud auditory stimulus. Higher the score, greater is the depth of sedation. Use of ketamine usually provides a depth of sedation of 5 or 6.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O2" value="6" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O3" value="6" lower_limit="5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain</title>
        <description>Measure pain using self reported Wong Baker faces pain rating scale prior to sedation, during sedation and prior to discharge.The scale shows a series of faces ranging from a happy face at 0, &quot;No hurt&quot; to a crying face at 10 &quot;Hurts worst&quot;. The patient must choose the face that best describes how they are feeling. The score has values of 0(no hurt), 2(hurts little bit), 4(hurts little more), 6(hurts even more), 8(hurts whole lot),10 (hurts worst). The patient chooses one number that describes the pain best (eg. Either a 2 or 4).</description>
        <time_frame>Patients will be assessed during the procedure after administration of sedation medicaiton. Approximately 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine IV 1 mg/kg</title>
            <description>Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
Ketamine IV 1mg/kg: Intervention: Ketamine IV 1mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Ketamine IV 1.5 mg/kg</title>
            <description>Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
Ketamine IV 1.5mg/kg: Intervention: Ketamine IV 1.5 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Ketamine IV 2 mg/kg</title>
            <description>Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
Ketamine IV 2mg/kg: Intervention: Ketamine IV 2 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Measure pain using self reported Wong Baker faces pain rating scale prior to sedation, during sedation and prior to discharge.The scale shows a series of faces ranging from a happy face at 0, &quot;No hurt&quot; to a crying face at 10 &quot;Hurts worst&quot;. The patient must choose the face that best describes how they are feeling. The score has values of 0(no hurt), 2(hurts little bit), 4(hurts little more), 6(hurts even more), 8(hurts whole lot),10 (hurts worst). The patient chooses one number that describes the pain best (eg. Either a 2 or 4).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sedation Duration</title>
        <description>Length of sedation was defined as the time duration from the administration of study medication until ready for discharge using standardized discharge criteria (Aldrete scoring &gt;9) followed at our institution.</description>
        <time_frame>Patients will be assessed during the length of time from administration of sedation medication until ready for discharge, Approximately 3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine IV 1 mg/kg</title>
            <description>Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
Ketamine IV 1mg/kg: Intervention: Ketamine IV 1mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Ketamine IV 1.5 mg/kg</title>
            <description>Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
Ketamine IV 1.5mg/kg: Intervention: Ketamine IV 1.5 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Ketamine IV 2 mg/kg</title>
            <description>Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
Ketamine IV 2mg/kg: Intervention: Ketamine IV 2 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Sedation Duration</title>
          <description>Length of sedation was defined as the time duration from the administration of study medication until ready for discharge using standardized discharge criteria (Aldrete scoring &gt;9) followed at our institution.</description>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="19" upper_limit="38"/>
                    <measurement group_id="O2" value="24.5" lower_limit="17.5" upper_limit="34.5"/>
                    <measurement group_id="O3" value="23" lower_limit="19" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Additional Dose</title>
        <description>Number of participants to whom additional doses of ketamine administered apart from the study dose</description>
        <time_frame>Patients will be assessed during procedure . Approximately 1 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine IV 1 mg/kg</title>
            <description>Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
Ketamine IV 1mg/kg: Intervention: Ketamine IV 1mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Ketamine IV 1.5 mg/kg</title>
            <description>Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
Ketamine IV 1.5mg/kg: Intervention: Ketamine IV 1.5 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Ketamine IV 2 mg/kg</title>
            <description>Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
Ketamine IV 2mg/kg: Intervention: Ketamine IV 2 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Additional Dose</title>
          <description>Number of participants to whom additional doses of ketamine administered apart from the study dose</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Adverse events secondary to sedation experienced by the patient and interventions performed to overcome them</description>
        <time_frame>Patients will be assessed after administration of medication until discharge and will have a follow up phone call 48 hours after discharge for 3 attempts. 5 days.,</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine IV 1 mg/kg</title>
            <description>Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
Ketamine IV 1mg/kg: Intervention: Ketamine IV 1mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Ketamine IV 1.5 mg/kg</title>
            <description>Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
Ketamine IV 1.5mg/kg: Intervention: Ketamine IV 1.5 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Ketamine IV 2 mg/kg</title>
            <description>Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
Ketamine IV 2mg/kg: Intervention: Ketamine IV 2 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Adverse events secondary to sedation experienced by the patient and interventions performed to overcome them</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse events in ED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post discharge Emesis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Adverse events in ED</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Post discharge Emesis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sedation Satisfaction</title>
        <description>Consultants will be asked to rate their level of satisfaction with sedation on a Likert Scale of 1-3</description>
        <time_frame>At the end of the procedure. Approximately 1 hour</time_frame>
        <population>consultant satisfaction missing in 6 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine IV 1 mg/kg</title>
            <description>Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
Ketamine IV 1mg/kg: Intervention: Ketamine IV 1mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Ketamine IV 1.5 mg/kg</title>
            <description>Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
Ketamine IV 1.5mg/kg: Intervention: Ketamine IV 1.5 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Ketamine IV 2 mg/kg</title>
            <description>Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
Ketamine IV 2mg/kg: Intervention: Ketamine IV 2 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Sedation Satisfaction</title>
          <description>Consultants will be asked to rate their level of satisfaction with sedation on a Likert Scale of 1-3</description>
          <population>consultant satisfaction missing in 6 participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketamine IV 1 mg/kg</title>
          <description>Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
Ketamine IV 1mg/kg: Intervention: Ketamine IV 1mg/kg</description>
        </group>
        <group group_id="E2">
          <title>Ketamine IV 1.5 mg/kg</title>
          <description>Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
Ketamine IV 1.5mg/kg: Intervention: Ketamine IV 1.5 mg/kg</description>
        </group>
        <group group_id="E3">
          <title>Ketamine IV 2 mg/kg</title>
          <description>Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
Ketamine IV 2mg/kg: Intervention: Ketamine IV 2 mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Emesis</sub_title>
                <description>Vomiting during/post sedation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Unpleasant Recovery Reaction</sub_title>
                <description>agitation, hallucinations</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oxygen Desaturation</sub_title>
                <description>Pulse oximetry &lt;90% in room air</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Others</sub_title>
                <description>Rash</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Convenience sample of patients enrolled. One fourth of patients did not receive the dose that they were randomized to. We did not enroll children &lt;3 years. We did not randomize by procedure type which could have confounded length of sedation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nirupama Kannikeswaran</name_or_title>
      <organization>Children's Hospital of Michigan</organization>
      <phone>313-745-5260</phone>
      <email>nkannike@dmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

